1.4 million thanks!

Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email

Just registered the 1,400,000th view of my blog site.  So grateful for the support!

Last 12 posts going back to 28th June – feel free to read and share.  Each one has a share button for Facebook, Twitter, Pinterest, WhatsApp and Email (as has the entire post).

You can also catch up on other points of interest and some of my lockdown activities on my Facebook pages Ronny Allan and Neuroendocrine Cancer

Many thanks

Ronny

Patient Advocacy
Ronny Allan

External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy

Peptide Receptor Radionuclide Therapy (PRRT) has been around for a while and doctors are learning all the time about the most likely candidates. Selection of

Read More »
Clinical Trials
Ronny Allan

Clinical Trial: Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)

Whenever I post about a new trial or study, some people get excited without understanding that these new treatments and capabilities can very often take

Read More »
Awareness
Ronny Allan

Blog review and top 10 for 2021: RonnyAllan.NET

I should be happy with over a quarter of a million views in 2021 but I’m not!  Like 2020, my figures are down on previous

Read More »
Diet and Nutrition
Ronny Allan

Neuroendocrine Cancer Diarrhea- building the jigsaw: Bile Acid Malabsorption

With Neuroendocrine Cancer patients, the mention of “diarrhea” is a topical subject.  There’s the usual claim that it’s caused by carcinoid syndrome and for some

Read More »
Clinical Trials
Ronny Allan

177Lu-DOTA-LM3 – a novel radionuclide therapy proven safe and effective to treat neuroendocrine neoplasms (NEN)

This is all the information available and further details to follow if any is published.  Remember, this is not yet an approved treatment, nor is

Read More »
Patient Advocacy
Ronny Allan

Small Intestine Neuroendocrine Tumours: “No other cancer really looks like this”

It’s known that Neuroendocrine Cancer is quite different in many ways from other cancers, notwithstanding the misnomer term carcinoid which is thankfully being slowly moved

Read More »
Patient Advocacy
Ronny Allan

20th November 2010 – feeling perkier

Every year I cast my mind back to this time in 2010. Diagnosed on 26th July that year, I was in hospital from 8th –

Read More »
Treatment
Ronny Allan

Do we need a new model for Carcinoid Crisis in NETs?

(so called) Carcinoid Crisis is one thing that tends to raise concerns in patients and has been bubbling away in NET centres and in patient

Read More »
Clinical Trials
Ronny Allan

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)

Some of the key differences between Lanreotide and Octreotide long-acting are:1.  Octreotide long-acting needs constituting prior to administration – Lanreotide comes prefilled.  2. Octreotide long-acting

Read More »

I love comments - feel free!

%d bloggers like this: